A phase I dose finding study of an experimental new drug, PPAR [peroxisome proliferator-activated receptor] agonist taken by mouth by patients with advanced or metastatic cancer.

Trial Profile

A phase I dose finding study of an experimental new drug, PPAR [peroxisome proliferator-activated receptor] agonist taken by mouth by patients with advanced or metastatic cancer.

Completed
Phase of Trial: Phase I

Latest Information Update: 21 Aug 2017

At a glance

  • Drugs Efatutazone (Primary)
  • Indications Cancer
  • Focus Adverse reactions; Biomarker
  • Most Recent Events

    • 23 Feb 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov. (NCT00408434)
    • 23 Feb 2010 Actual end date (Feb 2010) added as reported by ClinicalTrials.gov. (NCT00408434).
    • 18 Dec 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top